Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Folate Conjugated Solid Lipid Nanoparticle: Formulation Development, Optimization, and Characterization

Author(s): Vaibhav Rajoriya, Varsha Kashaw and Sushil Kumar Kashaw*

Volume 11, Issue 3, 2021

Published on: 30 December, 2021

Page: [186 - 199] Pages: 14

DOI: 10.2174/2468187311666211201111858

Price: $65

conference banner
Abstract

Objective: The current paper represents the development, optimization, and characterization of paclitaxel-loaded folate conjugated solid lipid nanoparticles (FA-SLNs).

Methods: The ligand (FA-SLNs) conjugated and non-conjugated SLNs (PTX-SLNs) were prepared by the hot homogenization method. The formulations (FA-SLNs and PTX-SLNs) were optimized with various parameters, i.e., drug loading, stirring time, stirring speed, particle size, and polydispersity index, and characterized. The in-vitro drug release study was performed in different pH environments by using the dialysis bag method. The surface morphology and particle size were determined through scanning electron microscopy and Transmission Electron Microscopy respectively. The SLNs formulations were also evaluated for the stability study.

Result: The particle size of PTX-SLNs and FA-SLNs was determined and found to be 190.1±1.9 and 231.3±2.3 nm, respectively. The surface morphology of the SLNs indicates that the prepared formulations are round-shaped and show smooth surfaces. The TEM study indicated that particles were in the range of 100-300 nm. The entrapment efficiency and drug loading capacity of FASLNs were found to be 79.42±1.6% and 17.3±1.9%, respectively. In-vitro drug release study data stated that the optimum drug release was found in an acidic environment at pH 4.0, that showed 94.21% drug release after 16 hours, and it demonstrates that FA-SLNs with an optimized formulation will provide a more sustained and effective release in tumor tissue that is exposed to an acidic environment as a result of the angiogenesis process.

Conclusion: In this research paper, different formulation parameters, found to influence the fabrication of drugs into Solid lipid nanoparticles, were optimized for high entrapment efficiency and drug loading. The most important parameters were drug:lipid ratio, drug: polymer ratio, and lipid:- surfactant ratio. Higher in-vitro drug release was observed in pH 4 as compared to pH 7.4. These result data concludes that FA-SLNs formulation was successfully prepared, optimized, and characterized.

Keywords: Solid lipid nanoparticles, folate, particle size, drug loading, paclitaxel, drug release.

« Previous
Graphical Abstract

[1]
Brigger C, Dubernet P, Couvreur A. Nanoparticle in cancer therapy and diagnosis. Adv Drug Deliv Rev 2012; 3(2): 10-5.
[http://dx.doi.org/10.1016/S0169-409X(02)00044-3]
[2]
Paliwal R, Rai S, Vaidya B, et al. Cell-selective mitochondrial targeting: progress in mitochondrial medicine. Curr Drug Deliv 2007; 4(3): 211-24.
[http://dx.doi.org/10.2174/156720107781023910] [PMID: 17627495]
[3]
Chan JM, Zhang L, Tong R, et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci USA 2010; 107(5): 2213-8.
[http://dx.doi.org/10.1073/pnas.0914585107] [PMID: 20133865]
[4]
Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev 2012; 3: 184-96.
[http://dx.doi.org/10.3402/nano.v3i0.18496] [PMID: 23240070]
[5]
Gastaldi L, Battaglia L, Peira E, et al. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm 2014; 87(3): 433-44.
[http://dx.doi.org/10.1016/j.ejpb.2014.05.004] [PMID: 24833004]
[6]
Zhang YL, Zhang ZH, Jiang TY, et al. Cell uptake of paclitaxel solid lipid nanoparticles modified by cell-penetrating peptides in A549 cells. Pharmazie 2013; 68(1): 47-53.
[PMID: 23444780]
[7]
Jain A, Agarwal A, Majumder S, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 2010; 148(3): 359-67.
[http://dx.doi.org/10.1016/j.jconrel.2010.09.003] [PMID: 20854859]
[8]
Tsai MJ, Huang YB, Wu PC, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci 2011; 100(2): 547-57.
[http://dx.doi.org/10.1002/jps.22285] [PMID: 20740670]
[9]
Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 2008; 348(1-2): 137-45.
[http://dx.doi.org/10.1016/j.ijpharm.2007.07.012] [PMID: 17714896]
[10]
Mussi SV, Silva RC, Oliveira MC, Lucci CM, Azevedo RB, Ferreira LA. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci 2013; 48(1-2): 282-90.
[http://dx.doi.org/10.1016/j.ejps.2012.10.025] [PMID: 23178339]
[11]
Yang T, Sheng HH, Feng NP, Wei H, Wang ZT, Wang CH. Preparation of andrographolide-loaded solid lipid nanoparticles and their in vitro and in vivo evaluations: characteristics, release, absorption, transports, pharmacokinetics, and antihyperlipidemic activity. J Pharm Sci 2013; 102(12): 4414-25.
[http://dx.doi.org/10.1002/jps.23758] [PMID: 24166599]
[12]
Sahu PK, Mishra DK, Jain N, Rajoriya V, Jain AK. Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel. Drug Dev Ind Pharm 2015; 41(4): 640-9.
[http://dx.doi.org/10.3109/03639045.2014.891130] [PMID: 24564799]
[13]
Mosallaei N, Jaafari MR, Hanafi-Bojd MY, Golmohammadzadeh S, Malaekeh-Nikouei B. Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations. J Pharm Sci 2013; 102(6): 1994-2004.
[http://dx.doi.org/10.1002/jps.23522] [PMID: 23558514]
[14]
Shenoy VS, Gude RP, Murthy RSR. Paclitaxel-loaded glyceryl palmitostearate nanoparticles: in vitro release and cytotoxic activity. J Drug Target 2009; 17(4): 304-10.
[http://dx.doi.org/10.1080/10611860902737938] [PMID: 19255897]
[15]
Müller C, Schibli R. Folic acid conjugates for nuclear imaging of folate receptor-positive cancer. J Nucl Med 2011; 52(1): 1-4.
[http://dx.doi.org/10.2967/jnumed.110.076018] [PMID: 21149477]
[16]
Carbone C, Campisi A, Musumeci T, Raciti G, Bonfanti R, Puglisi G. FA-loaded lipid drug delivery systems: preparation, characterization and biological studies. Eur J Pharm Sci 2014; 52: 12-20.
[http://dx.doi.org/10.1016/j.ejps.2013.10.003] [PMID: 24514450]
[17]
Mansoori GA, Brandenburg KS, Shakeri-Zadeh A. A comparative study of two folate-conjugated gold nanoparticles for cancer nanotechnology applications. Cancers (Basel) 2010; 2(4): 1911-28.
[http://dx.doi.org/10.3390/cancers2041911] [PMID: 24281209]
[18]
Liu Z, Zhong Z, Peng G, et al. Folate receptor mediated intracellular gene delivery using the charge changing solid lipid nanoparticles. Drug Deliv 2009; 16(6): 341-7.
[http://dx.doi.org/10.1080/10717540903047387] [PMID: 19606948]
[19]
Bilthariya U, Jain N, Rajoriya V, Jain AK. Folate-conjugated albumin nanoparticles for rheumatoid arthritis-targeted delivery of etoricoxib. Drug Dev Ind Pharm 2015; 41(1): 95-104.
[http://dx.doi.org/10.3109/03639045.2013.850705] [PMID: 24164469]
[20]
Dubey RD, Alam N, Saneja A, et al. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine. Int J Pharm 2015; 492(1-2): 80-91.
[http://dx.doi.org/10.1016/j.ijpharm.2015.07.012] [PMID: 26165611]
[21]
Gawde KA, Kesharwani P, Sau S, et al. Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue. J Colloid Interface Sci 2017; 496: 290-9.
[http://dx.doi.org/10.1016/j.jcis.2017.01.092] [PMID: 28236692]
[22]
Li R, Eun JS, Lee MK. Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration. Arch Pharm Res 2011; 34(2): 331-7.
[http://dx.doi.org/10.1007/s12272-011-0220-2] [PMID: 21380818]
[23]
Jain SK, Chaurasiya A, Gupta Y, et al. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul 2008; 25(5): 289-97.
[http://dx.doi.org/10.1080/02652040701799598] [PMID: 18608808]
[24]
Wu L, Tang C, Yin C. Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol). Drug Dev Ind Pharm 2010; 36(4): 439-48.
[http://dx.doi.org/10.3109/03639040903244472] [PMID: 19824865]
[25]
Mehrotra A, Pandit JK. Preparation and characterization and biodistribution studies of lomustine loaded PLGA nanoparticles by interfacial deposition method. J Nanomed Nanotechnol 2015; 6: 328-32.
[http://dx.doi.org/10.4172/2157-7439.1000328]
[26]
Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem 1978; 90(2): 809-15.
[http://dx.doi.org/10.1016/0003-2697(78)90172-0] [PMID: 727510]

Rights & Permissions Print Cite
Article Metrics
11
3
1
© 2024 Bentham Science Publishers | Privacy Policy